Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial

Jasvinder A Singh, Nipam Shah, Candace Green, Jasvinder A Singh, Nipam Shah, Candace Green

Abstract

Background: Systemic Lupus erythematosus (SLE), also commonly referred to as lupus, is a rare, but sometimes, fatal disease, that primarily affects young women. Lupus nephritis, a common manifestation of lupus, is more common and more devastating in patients of minority race/ethnicity. Patients have negative views of immunosuppressive drugs for lupus nephritis due to a concern about side effects and under-appreciation of its benefit. We designed a study to assess the effectiveness of individualized, computerized patient decision-aid for immunosuppressive drugs for lupus nephritis compared to a standard pamphlet for patient decision-making.

Methods: Adult women with lupus nephritis, with a current lupus nephritis flare or at risk of a future lupus nephritis flare will be randomized to individualized, computerized patient decision-aid for immunosuppressive drugs vs. standard pamphlet with information about lupus and its treatment including immunosuppressive drugs and outcomes. Patients will complete outcome assessments immediately after the intervention has been administered. Patients will be followed at 3-months with a brief survey, either in person or on the phone, and at 6-months with medical record review for exploratory outcomes. Co-primary outcomes are decisional conflict and informed choice regarding immunosuppressive drugs (combines values, knowledge and choice). Secondary outcomes include: (1) assessment of patient-physician communication by assessing audio-taped physician-patient communication after intervention administration; (2) concordance between patient's desired and actual role in immunosuppressive drugs decision-making using the control preference scale (CPS); and (3) patient perception of physician interaction using the interpersonal process of care- short form (IPC-SF).

Discussion: This is one of the first studies to evaluate the effectiveness of an educational intervention targeting minorities with lupus nephritis. This patient-centered lupus nephritis decision-aid will be available in the public domain in English and Spanish.

Trial registration: ClinicalTrials.gov Identifier: NCT02319525 ; registered on November 5, 2014.

Keywords: Decision-aid; Lupus; Lupus nephritis; Minorities; Randomized controlled trial; Randomized trial; Women.

Figures

Fig. 1
Fig. 1
CONSORT diagram showing each stage of the randomized trial

References

    1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25. doi: 10.1002/art.23177.
    1. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157–65. doi: 10.1016/S0272-6386(00)70316-7.
    1. Odutola J, Ward MM. Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Curr Opin Rheumatol. 2005;17(2):147–52. doi: 10.1097/.
    1. Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus. 1999;8(3):197–209. doi: 10.1191/096120399678847704.
    1. Trends in deaths from systemic lupus erythematosus-United States, 1979–1998. MMWR Morb Mortal Wkly Rep. 2002;51(17):371–4.
    1. Krishnan E, Hubert HB. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis. 2006;65(11):1500–5. doi: 10.1136/ard.2005.040907.
    1. Alarcon GS, McGwin G, Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11(2):95–101. doi: 10.1191/9612332lu155oa.
    1. Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004;13(11):857–60. doi: 10.1191/0961203304lu2023oa.
    1. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine. 2006;85(3):147–56. doi: 10.1097/01.md.0000224709.70133.f7.
    1. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med. 1996;156(12):1337–44. doi: 10.1001/archinte.1996.00440110109015.
    1. Costenbader KH, Desai A, Alarcon GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681–8. doi: 10.1002/art.30293.
    1. Bernatsky S, Boivin JF, Joseph L, et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum. 2005;53(5):781–4. doi: 10.1002/art.21458.
    1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82(5):299–308. doi: 10.1097/01.md.0000091181.93122.55.
    1. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18(10):2039–46. doi: 10.1093/ndt/gfg345.
    1. Langford AT, Resnicow K, Roberts JS, Zikmund-Fisher BJ. Racial and ethnic differences in direct-to-consumer genetic tests awareness in HINTS 2007: sociodemographic and numeracy correlates. J Genet Couns. 2012;21(3):440–7. doi: 10.1007/s10897-011-9478-2.
    1. Cene CW, Roter D, Carson KA, Miller ER, 3rd, Cooper LA. The effect of patient race and blood pressure control on patient-physician communication. J Gen Intern Med. 2009;24(9):1057–64. doi: 10.1007/s11606-009-1051-4.
    1. Gordon HS, Street RL, Jr, Kelly PA, Souchek J, Wray NP. Physician-patient communication following invasive procedures: an analysis of post-angiogram consultations. Soc Sci Med. 2005;61(5):1015–25. doi: 10.1016/j.socscimed.2004.12.021.
    1. Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94(12):2084–90. doi: 10.2105/AJPH.94.12.2084.
    1. Manfredi C, Kaiser K, Matthews AK, Johnson TP. Are racial differences in patient-physician cancer communication and information explained by background, predisposing, and enabling factors? J Health Commun. 2010;15(3):272–92. doi: 10.1080/10810731003686598.
    1. Vina ER, Masi CM, Green SL, Utset TO. A study of racial/ethnic differences in treatment preferences among lupus patients. Rheumatology (Oxford) 2012;51(9):1697–706. doi: 10.1093/rheumatology/kes128.
    1. Vina ER, Utset TO, Hannon MJ, Masi CM, Roberts N, Kwoh CK. Racial differences in treatment preferences among lupus patients: a two-site study. Clin Exp Rheumatol. 2014;32(5):680–8.
    1. Tsang ASMW, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015;16(18):2793–806. doi: 10.1517/14656566.2015.1101448.
    1. Canetta PA, Bomback AS, Radhakrishnan J. Treating lupus in the kidney: where are we now, and where are we going? Discov Med. 2011;12(65):341–9.
    1. Osborn CY, Cavanaugh K, Wallston KA, White RO, Rothman RL. Diabetes numeracy: an overlooked factor in understanding racial disparities in glycemic control. Diabetes Care. 2009;32(9):1614–9. doi: 10.2337/dc09-0425.
    1. Waldrop-Valverde D, Osborn CY, Rodriguez A, Rothman RL, Kumar M, Jones DL. Numeracy skills explain racial differences in HIV medication management. AIDS Behav. 2010;14(4):799–806. doi: 10.1007/s10461-009-9604-4.
    1. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009;48(3):266–71. doi: 10.1093/rheumatology/ken479.
    1. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913–9.
    1. Kumar K, Gordon C, Barry R, Shaw K, Horne R, Raza K. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837–44. doi: 10.1177/0961203311398512.
    1. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 2002;47(6):630–8. doi: 10.1002/art.10790.
    1. Singh JA, Hossain A, Kotb A, Wells GA. Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Syst Rev. 2016;5(1):155. doi: 10.1186/s13643-016-0328-z.
    1. Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137. doi: 10.1186/s12916-016-0673-8.
    1. Singh JA, Hossain A, Kotb A, et al. Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. J Rheumatol. 2016;1:jrheum-160041.
    1. Singh JA, Qu H, Yazdany J, Chatham W, Shewchuk R. Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. Arthritis Res Ther. 2015;17:367. doi: 10.1186/s13075-015-0883-z.
    1. Singh JA, Qu H, Yazdany J, Chatham W, Dall’era M, Shewchuk RM. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. J Rheumatol. 2015;42(9):1616–23. doi: 10.3899/jrheum.150168.
    1. Rheumatology ACo. 2016. . Accessed 20 Jan 2017.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010.
    1. Arozullah AM, Yarnold PR, Bennett CL, et al. Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care. 2007;45(11):1026–33. doi: 10.1097/MLR.0b013e3180616c1b.
    1. Lee SY, Stucky BD, Lee JY, Rozier RG, Bender DE. Short Assessment of Health Literacy-Spanish and English: a comparable test of health literacy for Spanish and English speakers. Health Serv Res. 2010;45(4):1105–20. doi: 10.1111/j.1475-6773.2010.01119.x.
    1. O’Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15(1):25–30. doi: 10.1177/0272989X9501500105.
    1. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001;4(2):99–108. doi: 10.1046/j.1369-6513.2001.00140.x.
    1. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns. 2002;48(1):87–91. doi: 10.1016/S0738-3991(02)00089-7.
    1. Degner LF, Russell CA. Preferences for treatment control among adults with cancer. Res Nurs Health. 1988;11(6):367–74. doi: 10.1002/nur.4770110604.
    1. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485–92. doi: 10.1001/jama.1997.03540420081039.
    1. Adams JR, Drake RE, Wolford GL. Shared decision-making preferences of people with severe mental illness. Psychiatr Serv. 2007;58(9):1219–21. doi: 10.1176/ps.2007.58.9.1219.
    1. Stewart AL, Napoles-Springer AM, Gregorich SE, Santoyo-Olsson J. Interpersonal processes of care survey: patient-reported measures for diverse groups. Health Serv Res. 2007;42(3 Pt 1):1235–56. doi: 10.1111/j.1475-6773.2006.00637.x.
    1. O’Connor AM. User Manual - Decisional Conflict Scale (10 item question format) [document on the Internet]. © 1993 [updated 2010; cited YYYY MM DD]. 16 p. 2010. Available from : Ottawa Hospital Research Institute;: Ottawa: Ottawa Hospital Research Institute. Accessed 20 Jan 2017.
    1. Siminoff LA, Ravdin P, Colabianchi N, Sturm CM. Doctor-patient communication patterns in breast cancer adjuvant therapy discussions. Health Expect. 2000;3(1):26–36. doi: 10.1046/j.1369-6513.2000.00074.x.
    1. O’Connor AM. User Manual-Decisional Conflict Scale. © 1993 [updated 2010] 2003.
    1. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. Can J Nurs Res. 1997;29(3):21–43.
    1. Florin J, Ehrenberg A, Ehnfors M. Clinical decision-making: predictors of patient participation in nursing care. J Clin Nurs. 2008;17(21):2935–44. doi: 10.1111/j.1365-2702.2008.02328.x.
    1. Singh JA, Sloan JA, Atherton PJ, et al. Preferred roles in treatment decision making among patients with cancer: a pooled analysis of studies using the Control Preferences Scale. Am J Manag Care. 2010;16(9):688–96.
    1. Stewart AL, Napoles-Springer A, Perez-Stable EJ. Interpersonal processes of care in diverse populations. Milbank Q. 1999;77(3):305–39. doi: 10.1111/1468-0009.00138.
    1. Schillinger D, Handley M, Wang F, Hammer H. Effects of self-management support on structure, process, and outcomes among vulnerable patients with diabetes: a three-arm practical clinical trial. Diabetes Care. 2009;32(4):559–66. doi: 10.2337/dc08-0787.
    1. Napoles AM, Gregorich SE, Santoyo-Olsson J, O’Brien H, Stewart AL. Interpersonal processes of care and patient satisfaction: do associations differ by race, ethnicity, and language? Health Serv Res. 2009;44(4):1326–44. doi: 10.1111/j.1475-6773.2009.00965.x.
    1. Schenker Y, Stewart A, Na B, Whooley MA. Depressive symptoms and perceived doctor-patient communication in the Heart and Soul study. J Gen Intern Med. 2009;24(5):550–6. doi: 10.1007/s11606-009-0937-5.
    1. Street RL, Jr, Millay B. Analyzing patient participation in medical encounters. Health Commun. 2001;13(1):61–73. doi: 10.1207/S15327027HC1301_06.
    1. Cegala DJ, Street RL, Jr, Clinch CR. The impact of patient participation on physicians’ information provision during a primary care medical interview. Health Commun. 2007;21(2):177–85. doi: 10.1080/10410230701307824.
    1. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–2002. doi: 10.1001/jama.293.16.1995.
    1. Street RL, Jr, Gordon H, Haidet P. Physicians’ communication and perceptions of patients: is it how they look, how they talk, or is it just the doctor? Soc Sci Med. 2007;65(3):586–98. doi: 10.1016/j.socscimed.2007.03.036.
    1. Street RL, Jr, Richardson MN, Cox V, Suarez-Almazor ME. (Mis)understanding in patient-health care provider communication about total knee replacement. Arthritis Rheum. 2009;61(1):100–7. doi: 10.1002/art.24371.
    1. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009;169(17):1560–8. doi: 10.1001/archinternmed.2009.293.
    1. Fraenkel L, Peters E, Charpentier P, et al. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res . 2012;64(7):977–85.
    1. Saag KG, Mohr PE, Esmail L, et al. Improving the Efficiency and Effectiveness of Pragmatic Clinical Trials in Older Adults in the United States. [In press]. Contemporary Clinical Trials. 2012.
    1. Cohan D, Gomez E, Greenberg M, Washington S, Charlebois ED. Patient perspectives with abbreviated versus standard pre-test HIV counseling in the prenatal setting: a randomized-controlled, non-inferiority trial. PLoS One. 2009;4(4):e5166. doi: 10.1371/journal.pone.0005166.
    1. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ. 2010;341:c5370. doi: 10.1136/bmj.c5370.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever